Trial · NCT02276963
Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses
NCT02276963, Phase 1, Completed, Johns Hopkins University; results first posted 2019-06-06
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses. Trials, record NCT02276963. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02276963
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses
- NCT number
- NCT02276963
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 6 participants, actual
- Lead sponsor
- Johns Hopkins University
- Conditions
- Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
- Interventions
- Ublituximab
- First posted
- 2014-10-28
- Last updated
- 2019-06-06
- Results first posted
- 2019-06-06
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Neurological Disability - Expanded Disability Scale Score | On admission to the hospital on day 1, on discharge 5-21 days later and on follow up at 90 days | The Kurtzke Expanded Disability Status Scale (EDSS) was developed to measure the disability status of subjects with demyelinating disease. It allows an objective quantification of the level of functioning that could be widely and reproducibly used by researchers and health care providers. The EDSS provides a total score on a scale that ranges from 0 to 10 where 0 is normal and 10 is deceased. Increasing disability is reflected in an increasing EDSS score. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Neurological Disability - Expanded Disability Scale Score | On admission to the hospital on day 1, on discharge 5-21 days later and on follow up at 90 days | 5 subjects had EDSS measurements at the first three time points: baseline, admission and discharge. 3 subjects had EDSS scores with an additional EDSS measurement at 90-day follow up. | EDSS unit score | MEDIAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Neurological Disability - Expanded Disability Scale Score | Ublituximab Plus Glucocorticoids | Baseline | 4.0 | Inter-Quartile Range 2.25 to 5.5 | EDSS unit score |
| Change in Neurological Disability - Expanded Disability Scale Score | Ublituximab Plus Glucocorticoids | Admission | 6.5 | Inter-Quartile Range 5.25 to 7.5 | EDSS unit score |
| Change in Neurological Disability - Expanded Disability Scale Score | Ublituximab Plus Glucocorticoids | Discharge | 6.5 | Inter-Quartile Range 4.75 to 7.5 | EDSS unit score |
| Change in Neurological Disability - Expanded Disability Scale Score | Ublituximab Plus Glucocorticoids | 90-day follow up | 4.0 | Inter-Quartile Range 2.0 to 8.0 | EDSS unit score |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Ublituximab Plus Glucocorticoids | 6 | |
| Overall Study | COMPLETED | Ublituximab Plus Glucocorticoids | 3 | |
| Overall Study | NOT COMPLETED | Ublituximab Plus Glucocorticoids | 3 |
Source ClinicalTrials.gov
Adverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Headache/body ache | Musculoskeletal and connective tissue disorders | Ublituximab Plus Glucocorticoids | 3 | 5 | 3 |
| other | Leukopenia | Blood and lymphatic system disorders | Ublituximab Plus Glucocorticoids | 1 | 5 | 1 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Ublituximab Plus Glucocorticoids | 0 | 5 |
| Total, other adverse events | Ublituximab Plus Glucocorticoids | 3 | 5 |
| Total, serious adverse events | Ublituximab Plus Glucocorticoids | 0 | 5 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02276963
GET https://conductscience.org/api/trials/v1/NCT02276963/registered